Compass Therapeutics (CMPX) Competitors $2.76 +0.12 (+4.34%) As of 02:51 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CMPX vs. ETNB, ANIP, MESO, EWTX, JANX, TVTX, CVAC, CALT, GPCR, and AUPHShould you be buying Compass Therapeutics stock or one of its competitors? The main competitors of Compass Therapeutics include 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Mesoblast (MESO), Edgewise Therapeutics (EWTX), Janux Therapeutics (JANX), Travere Therapeutics (TVTX), CureVac (CVAC), Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry. Compass Therapeutics vs. Its Competitors 89BIO ANI Pharmaceuticals Mesoblast Edgewise Therapeutics Janux Therapeutics Travere Therapeutics CureVac Calliditas Therapeutics AB (publ) Structure Therapeutics Aurinia Pharmaceuticals 89BIO (NASDAQ:ETNB) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability. Do analysts prefer ETNB or CMPX? 89BIO currently has a consensus target price of $26.43, suggesting a potential upside of 149.56%. Compass Therapeutics has a consensus target price of $12.67, suggesting a potential upside of 358.11%. Given Compass Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than 89BIO.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89BIO 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.00Compass Therapeutics 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10 Is ETNB or CMPX more profitable? Compass Therapeutics' return on equity of -42.47% beat 89BIO's return on equity.Company Net Margins Return on Equity Return on Assets 89BION/A -81.44% -70.17% Compass Therapeutics N/A -42.47%-38.31% Which has higher earnings & valuation, ETNB or CMPX? Compass Therapeutics has higher revenue and earnings than 89BIO. Compass Therapeutics is trading at a lower price-to-earnings ratio than 89BIO, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89BION/AN/A-$367.08M-$3.38-3.13Compass Therapeutics$850K449.82-$49.38M-$0.41-6.74 Do institutionals & insiders hold more shares of ETNB or CMPX? 68.4% of Compass Therapeutics shares are held by institutional investors. 2.8% of 89BIO shares are held by company insiders. Comparatively, 29.8% of Compass Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor ETNB or CMPX? In the previous week, Compass Therapeutics' average media sentiment score of 0.86 beat 89BIO's score of 0.00 indicating that Compass Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment 89BIO Neutral Compass Therapeutics Positive Which has more volatility and risk, ETNB or CMPX? 89BIO has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. SummaryCompass Therapeutics beats 89BIO on 12 of the 14 factors compared between the two stocks. Get Compass Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CMPX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CMPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMPX vs. The Competition Export to ExcelMetricCompass TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$382.34M$2.92B$5.54B$8.99BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-6.7421.0627.5520.17Price / Sales449.82288.78432.66125.29Price / CashN/A41.1936.8257.86Price / Book3.047.808.105.60Net Income-$49.38M-$54.95M$3.17B$248.58M7 Day Performance5.53%5.88%4.21%5.33%1 Month Performance7.59%5.30%3.85%7.26%1 Year Performance219.28%7.96%34.49%21.87% Compass Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMPXCompass Therapeutics3.0829 of 5 stars$2.77+4.3%$12.67+358.1%+208.1%$382.34M$850K-6.7420ETNB89BIO1.5662 of 5 stars$9.82-0.4%$26.43+169.1%+25.9%$1.43BN/A-2.9140ANIPANI Pharmaceuticals3.4101 of 5 stars$65.25-0.4%$80.13+22.8%+4.3%$1.41B$614.38M-51.38600MESOMesoblast1.9853 of 5 stars$10.89-0.3%$18.00+65.3%+35.2%$1.39B$5.67M0.0080EWTXEdgewise Therapeutics2.6375 of 5 stars$13.11-0.5%$40.00+205.1%-37.8%$1.38BN/A-8.4660JANXJanux Therapeutics2.059 of 5 stars$23.10-0.2%$95.25+312.3%-38.0%$1.37B$10.59M-16.9930TVTXTravere Therapeutics3.3303 of 5 stars$14.80+0.2%$32.14+117.2%+75.5%$1.31B$233.18M-5.27460Gap UpCVACCureVac4.5018 of 5 stars$5.43+0.9%$6.83+25.8%+73.2%$1.22B$579.18M5.90880CALTCalliditas Therapeutics AB (publ)N/A$40.00flatN/AN/A$1.19B$1.60B-21.62180GPCRStructure Therapeutics2.6816 of 5 stars$20.74-1.6%$76.17+267.2%-49.7%$1.19BN/A-23.84136AUPHAurinia Pharmaceuticals2.7385 of 5 stars$8.47-2.0%$11.50+35.8%+34.8%$1.14B$235.13M30.25300 Related Companies and Tools Related Companies ETNB Alternatives ANIP Alternatives MESO Alternatives EWTX Alternatives JANX Alternatives TVTX Alternatives CVAC Alternatives CALT Alternatives GPCR Alternatives AUPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CMPX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Compass Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Compass Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
